Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP6074574B2 - 方法及び組成物 - Google Patents
[go: Go Back, main page]

JP6074574B2 - 方法及び組成物 - Google Patents

方法及び組成物 Download PDF

Info

Publication number
JP6074574B2
JP6074574B2 JP2010545546A JP2010545546A JP6074574B2 JP 6074574 B2 JP6074574 B2 JP 6074574B2 JP 2010545546 A JP2010545546 A JP 2010545546A JP 2010545546 A JP2010545546 A JP 2010545546A JP 6074574 B2 JP6074574 B2 JP 6074574B2
Authority
JP
Japan
Prior art keywords
polypeptide
peptide
phage
linking compound
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010545546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514803A (ja
Inventor
ウィンター，グレゴリー
ハイニス，クリスティアン
Original Assignee
バイシクル セラピューティクス リミテッド
バイシクル セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6074574(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0802079.4A external-priority patent/GB0802079D0/en
Priority claimed from GB0818399A external-priority patent/GB0818399D0/en
Application filed by バイシクル セラピューティクス リミテッド, バイシクル セラピューティクス リミテッド filed Critical バイシクル セラピューティクス リミテッド
Publication of JP2011514803A publication Critical patent/JP2011514803A/ja
Application granted granted Critical
Publication of JP6074574B2 publication Critical patent/JP6074574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
JP2010545546A 2008-02-05 2009-02-04 方法及び組成物 Active JP6074574B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0802079.4 2008-02-05
GBGB0802079.4A GB0802079D0 (en) 2008-02-05 2008-02-05 Method and compositions
GB0818399A GB0818399D0 (en) 2008-10-08 2008-10-08 Methods and compositions
GB0818399.8 2008-10-08
PCT/GB2009/000301 WO2009098450A2 (fr) 2008-02-05 2009-02-04 Procédés et compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015011208A Division JP6075658B2 (ja) 2008-02-05 2015-01-23 方法及び組成物

Publications (2)

Publication Number Publication Date
JP2011514803A JP2011514803A (ja) 2011-05-12
JP6074574B2 true JP6074574B2 (ja) 2017-02-08

Family

ID=40792924

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545546A Active JP6074574B2 (ja) 2008-02-05 2009-02-04 方法及び組成物
JP2015011208A Active JP6075658B2 (ja) 2008-02-05 2015-01-23 方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015011208A Active JP6075658B2 (ja) 2008-02-05 2015-01-23 方法及び組成物

Country Status (11)

Country Link
US (3) US8680022B2 (fr)
EP (5) EP2653545A1 (fr)
JP (2) JP6074574B2 (fr)
AT (1) ATE555200T1 (fr)
AU (1) AU2009211253B2 (fr)
CA (1) CA2714477C (fr)
DK (2) DK2257624T5 (fr)
ES (2) ES2383191T3 (fr)
PL (1) PL2257624T3 (fr)
PT (1) PT2257624E (fr)
WO (1) WO2009098450A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160057198A (ko) * 2014-11-13 2016-05-23 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
JP6092104B2 (ja) * 2010-08-13 2017-03-08 ミティ・バイオシステムズ・ゲーエムベーハー 修飾ペプチドディスプレイ
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
CN103796681B (zh) 2011-06-30 2018-07-20 建新公司 T细胞活化的抑制剂
PL2764140T3 (pl) 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
JP2015508638A (ja) 2012-02-03 2015-03-23 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ ファージディスプレイを用いてペプチド誘導体ライブラリーを定量化するための方法
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
SG11201406769RA (en) 2012-05-10 2014-11-27 Massachusetts Inst Technology Agents for influenza neutralization
MX366886B (es) 2012-08-07 2019-07-30 Massachusetts Inst Technology Anticuerpos anti-virus del dengue y usos de los mismos.
DK3456734T3 (da) 2012-10-04 2022-04-19 Res Found Dev Serinproteasemolekyler og behandlinger
ES2732574T3 (es) * 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US9868767B2 (en) 2013-05-23 2018-01-16 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
ES2715379T3 (es) * 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
KR20160119806A (ko) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
US10822604B2 (en) 2014-05-02 2020-11-03 Morphosys Ag Peptide libraries
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
US10724034B2 (en) 2014-10-22 2020-07-28 The Governors Of The University Of Alberta Genetic encoding of chemical post-translational modification for phage-displayed libraries
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP6609099B2 (ja) * 2014-12-10 2019-11-20 キヤノン株式会社 放射線検出装置、及び放射線検出シート
AU2015371172B2 (en) 2014-12-22 2021-05-13 Lanthiopep B.V. Novel methods for displaying cyclic peptides on bacteriophage particles
EP3286314B1 (fr) * 2015-04-23 2019-06-26 H. Hoffnabb-La Roche Ag Procédé et composition de polypeptide d'échafaudage d'anticorps bovin
JP2015214568A (ja) * 2015-07-13 2015-12-03 バイスクル・セラピューティクス・リミテッド 多重特異性ペプチド
CA3014921A1 (fr) 2016-02-16 2017-08-24 Research Development Foundation Molecules modifiees par sortase et utilisations de celles-ci
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
EP3467107B1 (fr) * 2016-06-07 2022-06-01 Kaneka Corporation Complexe d'affichage de ribosome et procédé de production associé
US11351222B2 (en) 2016-11-09 2022-06-07 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
WO2018098226A1 (fr) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Inhibiteur peptidyle bicyclique du facteur alpha de nécrose tumorale
WO2018098282A2 (fr) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Peptides cycliques pénétrant dans les cellules comprenant des motifs en épingle à cheveux et leurs procédés de fabrication et d'utilisation
EP3544621A1 (fr) 2016-11-27 2019-10-02 BicycleRD Limited Méthodes pour le traitement du cancer
JP7100034B2 (ja) 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2018115203A1 (fr) * 2016-12-23 2018-06-28 Bicyclerd Limited Dérivés peptidiques ayant de nouvelles structures de liaison
US20190389907A1 (en) * 2016-12-23 2019-12-26 Bicycletx Limited Peptide ligands for binding to mt1-mmp
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3635115A1 (fr) 2017-06-09 2020-04-15 Vib Vzw Inhibiteurs de glutamine déshydrogénase pour une utilisation dans la régénération musculaire
EP3645549A1 (fr) 2017-06-26 2020-05-06 BicycleRD Limited Ligands peptidiques bicycliques à fractions détectables et leurs utilisations
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
EP4036234A1 (fr) 2017-07-17 2022-08-03 Vib Vzw Méthode de dépistage des inhibiteurs de la synaptogyrine-3
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034868A1 (fr) 2017-08-14 2019-02-21 Bicyclerd Limited Conjugués peptide bicyclique-ligand ppr-a et leurs utilisations
WO2019034866A1 (fr) 2017-08-14 2019-02-21 Bicyclerd Limited Conjugués ligands peptidiques bicycliques et leurs utilisations
CA3078504A1 (fr) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Inhibiteurs peptidiques bicycliques
WO2019081714A1 (fr) 2017-10-26 2019-05-02 Vib Vzw Macrophages positifs à la podoplanine
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019148195A2 (fr) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Inhibiteurs peptidyliques cycliques du domaine de liaison cal-pdz
EP3752200A1 (fr) 2018-02-13 2020-12-23 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
EP3774851A1 (fr) 2018-04-04 2021-02-17 BicycleTX Limited Complexes peptidiques bicycliques hétérotandem
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
SG11202100721SA (en) * 2018-07-23 2021-02-25 Univ Alberta Genetically-encoded bicyclic peptide libraries
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020023620A1 (fr) * 2018-07-25 2020-01-30 Trustees Of Boston College Procédés et compositions de bibliothèques de bactériophages modifiés chimiquement
WO2020084305A1 (fr) 2018-10-23 2020-04-30 Bicycletx Limited Ligands peptidiques bicycliques et leurs utilisations
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
WO2020120984A1 (fr) 2018-12-13 2020-06-18 Bicycletx Limited Ligands peptidiques bicycliques spécifiques de mt1-mmp
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (fr) 2018-12-21 2020-06-25 Bicyclerd Limited Ligands peptidiques bicycliques spécifiques à pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
WO2020165600A1 (fr) 2019-02-14 2020-08-20 Bicycletx Limited Conjugués peptide-ligand bicyclique et leurs utilisations
WO2020178574A1 (fr) 2019-03-04 2020-09-10 Bicyclerd Limited Synthèse de conjugués de toxines bicycliques et leurs intermédiaires
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
WO2020225577A1 (fr) 2019-05-09 2020-11-12 Bicycletx Limited Ligands peptidiques bicycliques spécifiques à ox40
EP3976067A1 (fr) 2019-05-28 2022-04-06 Vib Vzw Lymphocytes t cd8 + dépourvus de plexines et leur application dans le traitement du cancer
WO2020239945A1 (fr) 2019-05-28 2020-12-03 Vib Vzw Traitement du cancer par ciblage des plexines dans le compartiment immunitaire
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2020325658A1 (en) 2019-08-07 2022-01-06 Gyros Protein Technologies AB A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
SMT202500247T1 (it) * 2019-10-03 2025-09-12 Bicycletx Ltd Complessi peptidici eterotandem biciclici
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
MX2022006001A (es) 2019-11-27 2022-10-27 Bicycletx Ltd Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
WO2021123767A1 (fr) 2019-12-16 2021-06-24 Bicycletx Limited Ligands peptidiques bicycliques spécifiques de l'il-17
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002706D0 (en) * 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
CN115768456A (zh) 2020-04-06 2023-03-07 拜斯科技术开发有限公司 Tslp特异性的双环肽配体
WO2021220011A1 (fr) 2020-05-01 2021-11-04 Bicycletx Limited Conjugués peptidiques bicycliques anti-infectieux
EP4149954A1 (fr) 2020-05-15 2023-03-22 BicycleTX Limited Conjugués peptidiques bicycliques anti-infectieux
CN115698720A (zh) 2020-06-12 2023-02-03 拜斯科技术开发有限公司 特征在于促红细胞生成素产生肝细胞受体a2(epha2)的过表达的疾病的治疗
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
CN111893577B (zh) * 2020-08-06 2022-03-22 厦门大学 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法
CA3186504A1 (fr) 2020-08-17 2022-02-24 Stephen J. Blakemore Conjugues "bicycle" specifiques de la nectine-4 et leurs utilisations
WO2022063957A1 (fr) 2020-09-24 2022-03-31 Vib Vzw Biomarqueur pour une thérapie antitumorale
WO2022063947A1 (fr) 2020-09-24 2022-03-31 Vib Vzw Combinaison d'inhibiteurs de p2y6 et d'inhibiteurs de points de contrôle immunitaire
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
KR20230107589A (ko) 2020-11-13 2023-07-17 바이사이클티엑스 리미티드 트랜스페린 수용체 1 (TfR1)에 특이적인 비시클릭 펩티드 리간드
DK4274838T3 (da) 2021-01-08 2024-10-21 Bicycletx Ltd Bicykliske peptidligander, der er specifikke for NK-celler
JP2024503642A (ja) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
JP2024504074A (ja) 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US20240083945A1 (en) 2021-01-08 2024-03-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20240083944A1 (en) 2021-01-08 2024-03-14 Bicycle TX Limited Anti-infective bicyclic peptide ligands
JP2024503641A (ja) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
AU2022206577A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
WO2022175392A1 (fr) 2021-02-17 2022-08-25 Vib Vzw Inhibition de slc4a4 dans le traitement du cancer
US11904020B2 (en) 2021-03-19 2024-02-20 Bicycletx Limited Bicyclic peptide ligands specific for TREM2
WO2022199804A1 (fr) 2021-03-24 2022-09-29 Vib Vzw Inhibition de nek6 pour traiter als et ftd
EP4326743A1 (fr) 2021-04-20 2024-02-28 BicycleTX Limited Ligands peptidiques bicycliques spécifiques de la p-sélectine
JP2024530943A (ja) 2021-08-06 2024-08-27 アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ がんの処置のための方法
CN118103075A (zh) 2021-09-03 2024-05-28 拜斯科技术开发有限公司 双环肽毒素偶联物及其中间体的合成
US12042509B2 (en) 2021-10-01 2024-07-23 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
GB202116263D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Anti-infective bicyclic peptide ligands
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy
GB202206431D0 (en) 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2024009108A1 (fr) 2022-07-07 2024-01-11 Bicycletx Limited Ligands peptidiques bicycliques anti-infectieux
WO2024160756A1 (fr) 2023-01-30 2024-08-08 Vib Vzw Suppresseurs de tauopathies
EP4676539A1 (fr) 2023-03-09 2026-01-14 BicycleTx Limited Synthèse de conjugués de toxine bicycliques, et intermédiaires de ceux-ci
WO2024248860A1 (fr) 2023-06-01 2024-12-05 Bicycletx Limited Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées
CN121889170A (zh) 2023-06-01 2026-04-17 拜斯科技术开发有限公司 对EphA2特异的双环肽配体及其用途
WO2024248859A1 (fr) 2023-06-01 2024-12-05 Bicycletx Limited Ligands peptidiques bicycliques spécifiques de la nectine 4 et leurs utilisations
CN121511098A (zh) 2023-06-01 2026-02-10 拜斯科技术开发有限公司 对nectin-4具有特异性的双环肽配体及其用途
CN121666391A (zh) 2023-06-07 2026-03-13 肽梦想株式会社 靶向磷脂酰肌醇蛋白聚糖-3的肽组合物及其用途
EP4731638A1 (fr) 2023-06-23 2026-04-29 BicycleTx Limited Ligands peptidiques bicycliques spécifiques des cellules nk
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
WO2025046244A1 (fr) 2023-09-01 2025-03-06 Bicycletx Limited Ligands peptidiques bicycliques se liant à tlr3
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
AU2024342769A1 (en) 2023-09-13 2026-04-23 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025067347A1 (fr) * 2023-09-28 2025-04-03 深圳湾实验室坪山生物医药研发转化中心 Complexe de particules de phage, son procédé de préparation et son utilisation
WO2025085724A1 (fr) * 2023-10-18 2025-04-24 University Of Utah Research Foundation Procédé enzymatique de synthèse de réticulations thioéther interpeptidiques
GB202316970D0 (en) 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2025125648A1 (fr) 2023-12-13 2025-06-19 Bicycletx Limited Complexe peptidique bicyclique destiné à être utilisé dans le traitement du cancer
WO2025125652A1 (fr) 2023-12-13 2025-06-19 Bicycletx Limited Polythérapie destinée à être utilisée dans le traitement du cancer
WO2025125809A1 (fr) 2023-12-13 2025-06-19 Bicycletx Limited Ligands peptidiques bicycliques spécifiques de la nectine-4 et leurs utilisations
WO2025191096A1 (fr) 2024-03-14 2025-09-18 Bicycletx Limited Peptide bicyclique
GB202410566D0 (en) 2024-07-19 2024-09-04 Bicycletx Ltd Computer implemented method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1998036743A1 (fr) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Composes poly-guanidino neuroprotecteurs bloquant les canaux a calcium n et p/q presynaptiques
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
WO2001023619A1 (fr) * 1999-09-29 2001-04-05 Xenoport, Inc. Composes exprimes sur materiels genetiques replicables, et methodes d'utilisation desdits composes
EP1385984A4 (fr) * 2001-03-21 2007-06-13 Xenoport Inc Composes presents a la surface de phages icosaedres et leurs procedes d'utilisation
WO2003089454A2 (fr) 2002-04-19 2003-10-30 California Institute Of Technology Bibliotheque de molecules d'acides nucleiques et de peptides dont les peptides contiennent des residus d'acides amines non naturels, et methodes de production associee
EP1452868A2 (fr) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Procédé pour sélectionner un médicament d'intérêt potentiel
WO2006078161A1 (fr) * 2005-01-24 2006-07-27 Pepscan Systems B.V. Composes liants, composes immunogenes et composes peptidomimetiques
WO2006095345A2 (fr) * 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Bacteriophages transportant des medicaments cibles
JP2009544697A (ja) * 2006-07-26 2009-12-17 ペプスキャン システムズ ベー．フェー． 免疫原性化合物及びタンパク質擬態物
EP2121007A1 (fr) * 2006-12-21 2009-11-25 Cytos Biotechnology AG Conjugues de peptides ccr5 circulaire et utilisation de ceux-ci

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160057198A (ko) * 2014-11-13 2016-05-23 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법
KR101693665B1 (ko) * 2014-11-13 2017-01-06 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법

Also Published As

Publication number Publication date
AU2009211253B2 (en) 2014-11-06
AU2009211253A1 (en) 2009-08-13
EP2257624B1 (fr) 2012-04-25
JP2015109856A (ja) 2015-06-18
EP2474613B1 (fr) 2014-07-16
WO2009098450A2 (fr) 2009-08-13
JP2011514803A (ja) 2011-05-12
DK2257624T5 (da) 2012-09-10
US20140187757A1 (en) 2014-07-03
PL2257624T3 (pl) 2012-09-28
EP2474613A1 (fr) 2012-07-11
US9670484B2 (en) 2017-06-06
ES2383191T9 (es) 2012-10-16
EP2257624B9 (fr) 2012-08-01
ATE555200T1 (de) 2012-05-15
US9657288B2 (en) 2017-05-23
EP2653544A1 (fr) 2013-10-23
EP2474613B2 (fr) 2022-02-16
WO2009098450A3 (fr) 2009-10-29
ES2509959T5 (en) 2024-12-19
US20150166988A1 (en) 2015-06-18
ES2383191T3 (es) 2012-06-19
JP6075658B2 (ja) 2017-02-08
US8680022B2 (en) 2014-03-25
EP2257624A2 (fr) 2010-12-08
DK2257624T3 (da) 2012-05-29
US20100317547A1 (en) 2010-12-16
DK2474613T3 (da) 2014-10-06
EP2653545A1 (fr) 2013-10-23
EP2653543A1 (fr) 2013-10-23
PT2257624E (pt) 2012-05-29
CA2714477C (fr) 2018-10-16
ES2509959T3 (es) 2014-10-20
CA2714477A1 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
JP6075658B2 (ja) 方法及び組成物
Heinis et al. Phage-encoded combinatorial chemical libraries based on bicyclic peptides
CA2751505C (fr) Peptides a specificite multiple
AU2014229994B2 (en) Modification of polypeptides
WO2006058226A9 (fr) Streptavidines dimeres modifiees et leurs utilisations
JP2013518807A (ja) 多重特異性ペプチド
US12371817B2 (en) Methods of making and utilizing amber-obligated phage display libraries
Hampton Development and Advancement of Phage Display Techniques for the Identification of Therapeutic Peptides
JP2015214568A (ja) 多重特異性ペプチド
Tharp II Expanding the Chemical Diversity of Phage-Displayed Peptide Libraries

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150123

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150130

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161027

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161125

R150 Certificate of patent or registration of utility model

Ref document number: 6074574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R150 Certificate of patent or registration of utility model

Ref document number: 6074574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250